Top 50 Biotech Startup Investors in October 2023

Portfolio highlights

• AIRNA — AIRNA is on a mission to transform the lives of patients with rare and common diseases by pioneering thediscovery and development of RNA editing therapeutics.
• Generate Biomedicines — Generate Biomedicines is a biotechnological company focusing on creating breakthrough medicines.
• Lightcast Discovery — Flexible control over droplet number, occupancy, location and movement. Enabling efficient, multi-step workflows with unprecedented flexibility.

Portfolio highlights

• Evozyne — We have a new way of thinking about proteins. We've uncovered Nature's hidden rules to build Natural Machines. With our partners, we are changing the world.
• Adela — Adela is focused on the detection of cancer and other high-morbidity, high-mortality conditions through a blood test.
• Iambic Therapeutics — Iambic has created a cutting-edge AI-driven platform to tackle the most challenging design problems in drug discovery and address unmet patient need.

Portfolio highlights

• Crescendo Biologics — Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments thatretain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.
• Sitryx Therapeutics — Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop first-in-class disease modifying therapeutics in immuno-oncology and immuno-inflammation. The company was co-founded by a team of world-leading scientists from the United States and Europe who have contributed significantly to the field of immunometabolism.Sitryx was founded in 2018 with seed funding from SV Health Investors and raised $30 million Series A funding from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Longwood Fund and GSK. The company has a pipeline of projects at multiple stages of drug discovery. Sitryx is headquartered in Oxford, UK.
• Tenpoint Therapeutics — Tenpoint Therapeutics is a biotechnology company pursuing vision-restoring engineered cell-based therapeutics.

Portfolio highlights

• Deka Biosciences — Deka BioSciences, Inc. is committed to developing and delivering life-changing medicines to patients with cancer and inflammatory diseases.
• Solu Therapeutics — Solu Therapeutics is a precision-medicine-focused company developing therapeutics to eliminate disease-driving cells.
• Arialys Therapeutics — Arialys Therapeutics is a pre-clinical stage company that develops auto-antibody focusing on neuroscience. The company focuses on how the immune system impacts CNS health, disease, and treatment.

Portfolio highlights

• Kate Therapeutics — Kate Therapeutics is a patient-focused biotechnology company developing AAV-based gene therapies to treat genetically defined muscle and heart diseases.
• Nexo Therapeutics — Nexo Therapeutics is a small molecule oncology company dedicated to the discovery and development of new drugs for cancer patients who currently lack meaningful therapies.
• Tentarix Biotherapeutics — Tentarix creates innovative protein therapeutics with uniquely combined bioactivities that leverage synthetic biology. The company develops a protein engineering platform designed for multispecific therapies.

Portfolio highlights

• Octave — Octave is a national behavioral health practice that’s creating a new standard for care delivery that’s both high-quality and accessible to more people. With in-person and virtual clinics in California and New York, the company offers personalized care plans that can include individual therapy, couples therapy, and groups, while pioneeringrelationships with payers to make care more affordable through insurance. Grounded in science, Octave enables clients to experience profound change that is as measurable as it is meaningful.
• Acesion Pharma — Acesion Pharma ApS is a Danish biotech company founded in 2011 and based in Copenhagen. Acesion Pharma develops more efficacious and safe drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia.
• Alentis Therapeutics — Alentis Therapeutics discovers and develops novel medications to treat advanced liver diseases.

Portfolio highlights

• Meeno — Meeno is a relationship mentoring app powered by generative AI
• Rocket.Chat — Explore Rocket.Chat, where we put data privacy into every conversation and enable teams to collaborate seamlessly.
• Pulumi — Pulumi's open source infrastructure as code SDK enables you to create, deploy, and manage infrastructure on any cloud, using your favorite languages.

Portfolio highlights

• K36 Therapeutics — K36 Therapeutics mission to translate epigenetic modulation of oncogenic pathways into first-in-class small molecule therapies.
• Nimbus Therapeutics — Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinicaldevelopment. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.
• Nvelop Therapeutics — Nvelop Therapeutics is a biotechnology company that provides gene editing technology services for unmet major disease needs.

Portfolio highlights

• Doceree — Doceree is a pharmaceutical advertising & healthcare marketing company which helps in getting a better healthcare services
• Avalyn Pharma — This does NOT display on the home page
• Nvelop Therapeutics — Nvelop Therapeutics is a biotechnology company that provides gene editing technology services for unmet major disease needs.

Portfolio highlights

• Spruce Biosciences — Developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need
• Nvelop Therapeutics — Nvelop Therapeutics is a biotechnology company that provides gene editing technology services for unmet major disease needs.
• Novome Biotechnologies — Novome Biotechnologies, Inc. is a biotechnology company focused on engineering defined activities into the human gut microbiota to treat chronic diseases. The Company has developed the first-ever platform for controlled colonization of the gut with engineered bacteria, enabling first-in-class living therapeutics: Genetically Engineered MicrobialMedicines (GEMMs). Novome is utilizing its proprietary GEMMs platform in its lead preclinical program in hyperoxaluria, which is focused on the development of a therapeutic strain of bacteria that degrades oxalate to prevent the formation of kidney stones. Efforts are also directed to the expansion of its proprietary synthetic biology platform into additional indications.

Portfolio highlights

• Deka Biosciences — Deka BioSciences, Inc. is committed to developing and delivering life-changing medicines to patients with cancer and inflammatory diseases.
• ReCode Therapeutics — ReCode is the first genetic medicines platform to enable highly targeted delivery to organs, tissues and cells beyond the liver. Our pipeline of rare disease therapeutics uses optimized mRNA and gene correction with redosing capability.
• Arialys Therapeutics — Arialys Therapeutics is a pre-clinical stage company that develops auto-antibody focusing on neuroscience. The company focuses on how the immune system impacts CNS health, disease, and treatment.

Portfolio highlights

• Isomark Health — Isomark Health is a patented AI-based, real-time and 100% green breath technology that detects and prevents bacterial and viral infections.
• Rantizo — Rantizo provides drone spraying systems and support services for custom applicators, agribusinesses and contractors. Elevating precision ag.
• Glanris — Glanris developed a completely green, non-toxic, filtration media for water purification from an agriculture by-product. This agricultural product is grown around the world, is plentiful, and can be used locally to ensure clean drinking water in developing countries. It also gives local farmers a significant additional income source for a productthat today they are throwing away.This media has been independently tested over the last two years of development and is ready for production.

Portfolio highlights

• Tausight — Tausight is specifically designed to help Healthcare ensure the confidentiality, integrity, and availability of ePHI.
• Candesant Biomedical — Candesant Biomedical develops treatment for excessive sweating and hyperhidrosis. It offers a technology that is based on the principle that alkali metals in contact with water generate energy. The insight was that when the amounts of metal and water are controlled, the result is targeted delivery of energy exactly at the site of the water. Itsdevice is designed to target and inactivate the most active sweat glands.The company was founded in 2016 and is headquartered in San Francisco, California.
• Crossbow Therapeutics — Crossbow Therapeutics is a seed-stage, stealth-mode oncology startup company. The company develops antibody engineering for intracellular cancer targets.

Portfolio highlights

• CellFE — CellFE is a company developing a microfluidics based device to deliver gene-editing molecules. CellFE developed microfluidic device and process that can efficiently deliver gene-editing molecules into the human cells.
• rabbit — Revolutionizing human-machine interaction
• Vayu Robotics — Vayu Robotics is an AI robotics company that develops and commercializes automotive sensing, autonomous vehicles, and robotics technology.

Portfolio highlights

• Hyku — Hyku Biosciences is developing the next generation of covalent medicines by targeting histidine, tyrosine and lysine binding pockets in disease-causing proteins.
• Hepalink — Hepalink is a manufactures ultra-pure pipeline control systems based on semiconductors and pan-semiconductor liquid circuits.
• Mediar Therapeutics — Mediar Therapeutics is a preclinical stage biotechnology company developing antibody-based therapeutics to halt fibrosis in a variety of organ systems, including lung, liver, kidney, and skin.

Portfolio highlights

• Hyku — Hyku Biosciences is developing the next generation of covalent medicines by targeting histidine, tyrosine and lysine binding pockets in disease-causing proteins.
• Adela — Adela is focused on the detection of cancer and other high-morbidity, high-mortality conditions through a blood test.
• SAB Biotherapeutics — A biopharmaceutical development company leading the science and manufacturing of antibody therapeutics. Utilizing some of the most advanced antibody science in the world, SAB is delivering the world’s first large-scale platform to create immunoglobulins. This natural production platform holds the potential for treatment of public health problems,rare conditions, long-term diseases and global pandemic threats.

Portfolio highlights

• Flare Therapeutics — Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets fortranscription factor regulation to address mutations that cause disease. Our drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation.
• Rapport Therapeutics — Precision medicines to match the complexity of the human brain.
• CARGO Therapeutics — CARGO Therapeutics develops CAR T-cell therapy to overcome cancer treatment resistance and address access barriers so that more patients can benefit from potentially curative therapies. The company is on a mission to outwit cancer by developing best-in-class chimeric antigen receptor (CAR) T-cell therapies. Despite commercially available autologousCARs advancements, these treatments are curative for less than half of all cancer patients. Furthermore, far too many patients are unable to access these potentially curative therapies due to other obstacles such as manufacturing, supply constraints, long turnaround times, and reimbursement barriers. CARGO's team is intensely focused on pursuing novel solutions to improve cancer treatment outcomes and experiences.

Portfolio highlights

• CellFE — CellFE is a company developing a microfluidics based device to deliver gene-editing molecules. CellFE developed microfluidic device and process that can efficiently deliver gene-editing molecules into the human cells.
• BeeOLED — BeeOLED’s technology enables OLED displays with significantly improved efficiency, brightness and operational stability at lower overall costs due to a less complex device structure.
• Lightcast Discovery — Flexible control over droplet number, occupancy, location and movement. Enabling efficient, multi-step workflows with unprecedented flexibility.

Portfolio highlights

• Acesion Pharma — Acesion Pharma ApS is a Danish biotech company founded in 2011 and based in Copenhagen. Acesion Pharma develops more efficacious and safe drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia.
• Actio Biosciences — At Actio, we are leveraging advances in genetics and precision medicine to develop life-changing treatments that target underlying shared biology between rare and common diseases. We are applying expertise in genetics, drug discovery, and data sciences to pinpoint targets that not only cause rare diseases with high unmet need, but that also hold promise in more common indications.
• Diligent Robotics — We build robots like Moxi that assist hospital staff with routine activities so they can focus on caring for patients.

Portfolio highlights

• Machine Discovery — Machine Discovery is a University of Oxford spin-out commercializing new machine learning technology. We leverage proprietary neural network technology to accelerate expensive calculations — and we do it with minimal data and 99.9% fidelity.
• Pencil Biosciences — Next Generation Genome Editing Tool
• Laverock Therapeutics — Laverock Therapeutics is developing a gene silencing platform for the creation of programmable, allogeneic cell therapies.

Portfolio highlights

• Nonna Lab — Make the Most. Le laboratoire qui vous rend la vie meilleure.
• Altior — Altior is an IT company that offers cloud industrial management software and ERP solution.
• Umiami — Umiami Technologies is a leader in plant-based meat. Our proprietary technology allows us to create clean-label and incredibly tasty foods.

Portfolio highlights

• Atantares — We are a development stage startup enabling the next generation of precision medicine by fusing biochip and AI technologies.
• Saints Sages Medical — Saints Sages Medical is engaged in the production and sales of minimally invasive surgical medical devices. They have several energy device products that are widely used in minimally invasive surgery, hepatobiliary surgery, gynecology, urology, thoracic surgery, and other departments. Saints Sages closely monitors clinical needs and develops moreinnovative minimally invasive surgical devices to serve global patients, relying on a professional research and development team and years of the clinical transformation experience.
• Epigenic Therapeutics — Epigenic Therapeutics is a biotech firm that offers gene editing therapy.

Portfolio highlights

• Senzo — SENZO HEALTH HAS DEVELOPED A REVOLUTIONARY LATERAL FLOW TEST WHICH DELIVERS THE SAME ACCURACY AS LABORATORY-BASED PCR, WITH RESULTS AVAILABLE WITHIN 10 MINUTES, AT A FRACTION OF THE COST.
• KayoThera — KayoThera is a biotechnology company developing therapeutics used to cure late-stage and metastatic cancers. Its programs work on inhibiting a key enzyme that is responsible for protecting the cancer cells and depleting regulatory T-cells that intends to cure hitherto incurable cancers and give hope to patients. The company's mission is todevelop the first-in-class immuno- and targeted therapies to drive cures in advanced cancersKayoThera was founded in 2019 and is headquartered in Princeton, New Jersey.
• Palvella Therapeutics — Palvella Therapeutics is committed to developing safe and effective therapies that specifically target the root cause of genetic skin diseases.

Portfolio highlights

• Inovedis — Inovedis offers innovative solutions in medical technology that contribute both to optimized patient care as well as time and cost reductions in the healthcare sector.
• Resourcify — Mein Recycling is developed by Resourcify GmbH from Hamburg. The app is the easiest solution for businesses to easily manage all of their waste, collections, and recyclers in one app, and for waste management companies to seamlessly connect with their customers online. Their vision is zero-waste: enabled with the digital transformation of the wastesector as the foundation for the circular economy.
• traceless materials — traceless materials offer a holistically sustainable alternative to plastics: 100% biobased on plant residues, compostable under natural conditions, and free of toxic chemicals. For a future free of pollution and waste!

Portfolio highlights

• Cerevance — Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.The company's therapeutics applies it's technology called NETSseq to reveal transcriptional and epigenetic differences between specific cell types in mature human brains, enabling healthcare providers to detect and tackle theearly onset of various neurological diseases.
• OncoResponse — OncoResponse Inc., an immuno-oncology company located in Houston, Texas, has partnered with MD Anderson Cancer Center (MDACC) to deploy a unique and transformational approach to cancer therapeutic monoclonal antibody and target discovery. The company licensed the I-STAR™ platform, developed and validated by Theraclone Sciences of Seattle, tointerrogate the human memory B-cell repertoire of cancer patients who are considered “Elite Responders” to immunotherapy; as such, their own adaptive immune system responded to immunotherapy stimulation in a way that achieved curative or durable responses. From these Elite Responders, OncoResponse is leveraging the human immune system to identify fully human monoclonal antibodies and discover novel targets that will lead to the development of fully human antibody derived therapeutics for the treatment of cancer.
• Larkspur Biosciences — Larkspur's strategy focuses on the particular ways in which tumours hijack the immune system by developing precision immunotherapies for molecularly defined patient groups to overcome the bottlenecks that allow the tumour to subvert the immune system.

Portfolio highlights

• Gridware — Using remote telemetry and edge AI, Gridware wildfire prevention technology powers a grid that is smarter and more reliable than ever before.
• BIOS — BIOS Health is unlocking the potential of the nervous system in treating chronic disease by using AI-powered neural interfaces that can automatically read and write neural signals.
• Elicit — Elicit is an artificial intelligence research assistant that uses language models to help users automate research workflows. This research assistant finds relevant papers without a perfect keyword match, summarizes takeaways from the papers, and extracts key information from the papers.

Portfolio highlights

• DiogenX — We incorporated DiogenX with the objective to provide new therapeutic solutions for diabetic patients. With Patrick Collombat and the team, we are focused on developing a first-in-class regenerative treatment for type 1 diabetes. Benjamin Charles CEO See the team News See more Our Work OUR APPROACH ABOUT DIABETES
• smartbax — We develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms.
• Rewind Therapeutics — Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medicalpractitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy.

Portfolio highlights

• Fore Biotherapeutics — We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics.
• Avalyn Pharma — This does NOT display on the home page
• Nimbus Therapeutics — Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinicaldevelopment. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.

Portfolio highlights

• FUE Bioscience — FUE Bioscience is a medical robot R&D business that specializes in microsurgery above the head and neck. It continues to develop a product matrix of fully intelligent, high-precision, and anthropomorphic surgical robots based on the platform of macro-micro-controlled humanoid dual-arm robots.
• Life Wilderness — Life Wilderness reimagines human-computer interaction and is linked to the transportation and travel industries.
• Xintu Heterogeneous — Xintu Heterogeneous offers data storage solutions for heterogeneous computing.

Portfolio highlights

• Nimbus Therapeutics — Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinicaldevelopment. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.
• ReCode Therapeutics — ReCode is the first genetic medicines platform to enable highly targeted delivery to organs, tissues and cells beyond the liver. Our pipeline of rare disease therapeutics uses optimized mRNA and gene correction with redosing capability.
• Crossbow Therapeutics — Crossbow Therapeutics is a seed-stage, stealth-mode oncology startup company. The company develops antibody engineering for intracellular cancer targets.

Portfolio highlights

• Noetik — Noetik is an AI-native biotechnology company. Our mission is to leverage advanced machine learning methods to discover and develop cancer immunotherapies.
• CH4 Global — CH4 Global is bending the curve with climate change solutions. We leverage red seaweed to help with methane reduction. Learn more our AgTech Solutions today!
• Mach Industries — Delivering decentralized warfare capabilities to guarantee the defense of freedom.

Portfolio highlights

• Akura Medical — Akura Medical is developing a next-generation thrombectomy device that aims to simplify thrombectomy through an easy-to-use, single-pass procedure that efficiently removes blood clots.
• Precede Biosciences — Precede Biosciences is revolutionizing precision medicine by revealing unprecedented insights into disease-defining biology from a simple blood test. Discover how we are helping create a world where medicine is developed more successfully, and every diagnosis is precise and minimally invasive.
• LYNK Pharmaceuticals — LYNK Pharmaceuticals is a biotech company focusing on the discovery and development of novel medicines to treat oncology, immunology, and inflammatory diseases. The company was founded in 2018 and is headquartered in Hangzhou, Zhejiang, China.

Portfolio highlights

• RoboK — A Cambridge University spin-out building cost-effective 3D sensing software technology
• Mogrify — Mogrify is pioneering a new class of in vivo reprogramming therapy and transforming the development of ex vivo cell therapy.
• PharmEnable — Designing the next generation of small molecule drugs. Replicating the specificity of biologics in the scalable form of a small molecule.

Portfolio highlights

• Sinay — Use the full potential of your data with intelligent solutions. Become more efficient on a daily basis and reduce your environmental impact.
• Allozymes — Allozymes, Pte. Ltd. is a leading deep technology company applying innovative ultrahigh-throughput microfluidics technology to accelerate enzyme evolution and development. We developed sensitive, accurate, and generic assays for the detection of enzymatic reactions, proprietary microfluidic chips and proteomics technologies to take enzymedevelopment to the next level.
• Vedanta Biosciences — Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing ofrationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily.It was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Portfolio highlights

• VarmX — VarmX is a pharmaceutical spin-off from the Leiden University Medical Center. The mission of VarmX is to develop and manufacture therapeutic proteins to instantaneously restore blood clotting in bleeding patients. The lead product in the pipeline of VarmX is PseudoXa. PseudoXa is a modified recombinant human coagulation factor X which is capable ofimmediately restoring blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban.These factor Xa coagulants are taken by millions of patients world-wide for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs. PseudoXa is capable of stopping and preventing such bleedings thus making the usage of DOACS much safer.
• Xeltis — Xeltis is pioneering a restorative approach in cardiovascular therapy.
• Evommune — Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines in inflammatory diseases.

Portfolio highlights

• Octave — Octave has developed the first of it's kind precision care solution focused on neurodegenerative diseases beginning with Multiple Sclerosis (MS).
• ROME Therapeutics — ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome – vast stretches of uncharted genetic material that have long been dismissed as “junk DNA.” With several drug targets identified and multiple discovery programs underway, ROME is moving rapidly to leverage this new frontier inbiology. To lead this exploration, ROME has assembled a team of world-class leaders across fields including oncology, immunology, virology and machine learning.
• Orbital Therapeutics — Orbital Therapeutics aims to enhance global health by unleashing the full potential of RNA-based medicines to treat human disease in ways that were not previously possible.

Portfolio highlights

• Metagenomi — Metagenomi is using the power of metagenomics and machine learning to discover novel genome editing systems.
• Pardes Biosciences — Pardes Biosciences is a clinical-stage biopharmaceutical company created by and for this moment to help solve pandemic-sized problems, starting with COVID-19. We are applying modern reversible-covalent chemistry as a starting point to discover and develop novel oral drug candidates while reimagining the patient journey to access these medicines.The company’s lead product candidate, PBI-0451, is being developed as a direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections, the virus responsible for COVID-19. Pardes Biosciences is on a mission to stop a pandemic and start a movement so patients everywhere can get well sooner.
• New Amsterdam Pharma — NewAmsterdam Pharma is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases.

Portfolio highlights

• Delphi — Delphi is digital cloning that scales time, monetizes knowledge, and interacts audience at scale.
• Ramp — Join thousands of forward-thinking businesses using Ramp to control spend, save time, and automate busywork.
• Pivotal Commware — Pivotal Commware was established in 2016 to commercialize a breakthrough in electromagnetic physics, Holographic Beam Forming™ (HBF). Years ago, Pivotal’s founders recognized that wireless demand for data would outgrow the complex coding, multiplexing and modulation schemes that network operators have deployed thus far. Beamforming was theanswer, but existing high cost, size, weight and power-consuming (C-SWaP) solutions were not. That’s why Pivotal assembled a team experienced in advanced commercial antenna and RF circuit design, advanced DARPA technology programs, and, uniquely, active/nonlinear metamaterials. Beyond technology, Pivotal also offers the depth and breadth of skills to develop integrated, end-to-end solutions.

Portfolio highlights

• OOVA — OOVA is a fertility diagnostic company that spun out from Mount Sinai Hospital in New York City. Using patent pending biochemistry and artificial intelligence, OOVA learns a woman’s fertility profile by accurately measuring key hormones over time through daily urine samples. By monitoring this critical balance of hormones, OOVA can help a woman getpregnant, identify reasons she is having trouble getting pregnant, and even expose reproductive health issues like PCOS.
• Raise Green — Raise Green is the climate tech marketplace for local impact investing licensed with the SEC and FINRA to sell private securities.
• Driver Technologies — Turn your phone into a dash cam.

Portfolio highlights

• Star Therapeutics — Star Therapeutics mission is to develop therapies for as many diseases as possible for millions of patients.
• Rapport Therapeutics — Precision medicines to match the complexity of the human brain.
• Alkeus Pharmaceuticals — Alkeus Pharmaceuticals is a Boston-based startup focused on treatments for serious ophthalmic conditions.

Portfolio highlights

• Castelion — We are a modern defense production company building the next generation of military hypersonic, vehicle, and strike systems to deter future wars.
• Headway — Headway is a mental healthcare system provider based in New York. It develops a health insurance advisory platform designed to connect patients with therapists and provides administrative support to therapists who don’t typically accept insurance. The company was founded by Andrew Adams, Jake Sussman, Dan Ross, and Kevin Chan in 2019.
• Blackbird — We believe the next great hospitality technology platform should connect restaurants and their customers directly, in meaningful and ongoing ways. Blackbird is founded by a team with a passion for restaurants and a track record of using technology to solve problems.

Portfolio highlights

• Cardiosense — Cardiosense offers a physiological waveform AI platform to develop predictive biomarkers for the detection and treatment of disease. Its platform leverages multi-modal sensors and industry-leading AI to develop predictive biomarkers for the detection and treatment of disease.
• Aer Therapeutics — Aer Therapeutics is a clinical stage biopharmaceutical company developing a novel inhaled approach to treat lung disease with excess mucus and mucus plugs.
• Mercy BioAnalytics — We are making early stage cancer 100,000x easier to find using extracellular vesicles found in blood, specific to their parent cells.

Portfolio highlights

• Midi Health — Expert care for women 40+. Made for midlife. Delivered by experienced clinicians. Covered by insurance. Book a visit today.
• Nimbus Therapeutics — Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinicaldevelopment. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.
• ROME Therapeutics — ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome – vast stretches of uncharted genetic material that have long been dismissed as “junk DNA.” With several drug targets identified and multiple discovery programs underway, ROME is moving rapidly to leverage this new frontier inbiology. To lead this exploration, ROME has assembled a team of world-class leaders across fields including oncology, immunology, virology and machine learning.

Portfolio highlights

• Octave — Octave has developed the first of it's kind precision care solution focused on neurodegenerative diseases beginning with Multiple Sclerosis (MS).
• Sound Agriculture — Sound Agriculture is creating a more agile and resilient food system with innovative on-demand crop solutions.
• Slingshot Biosciences — Precise, reliable, and repeatable results. With synthetic cell controls, these goals are achievable in your flow cytometry experiments. Reduce costs, save time and commercialize faster. Beads for spectral compensation, immunophenotyping, viability, and assay controls.

Portfolio highlights

• Synthekine — Discovering, Developing and Commercializing the Next Generation of Selective Cytokine Therapeutics. We believe that cytokine therapeutics engineered to be selective can fundamentally change the treatment paradigm of cancer and inflammatory disease.
• Cajal Neuroscience — Cajal Neuroscience is a drug discovery company focused on neurodegenerative disease.
• Carmot Therapeutics — Drug discovery and development to target the root causes that drive cancer and metabolic diseases using Chemotype Evolution.

Portfolio highlights

• ImmunoScape — ImmuniScape discovers and develops novel TCR-based therapeutics against solid tumors
• Inversago Pharma — Inversago Pharma is a preclinical-stage, biotech company specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists.
• Casma Therapeutics — Casma Therapeutics is a developer of a natural cellular process of autophagy to open new target areas for drug discovery and development. The company focuses on autophagy system to improve the cellular process of clearing out unwanted proteins, organelles and invading pathogens as well as tries to arrest or reverse the progression of lysosomalstorage disorders, muscle disorders, inflammatory disorders and neurodegeneration, enabling physicians to address unmet medical needs.

Portfolio highlights

• Bio-Images Drug Delivery — BDD Pharma combine drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and new innovative pharmaceutical products. Rapid parallel clinical testing with SWIFT significantly reduces time from product concept to clinical success.
• IOTech — Discover IOTech Systems, the open edge data platform for developing, deploying, and managing Industrial Edge applications at scale. Find out more here.
• Administrate — Manage 100% of enterprise training operations with configurable training management software, designed to scale with your organization.

Portfolio highlights

• InnoSIGN — We are passionate to bring to market our OncoSIGNal pathway activity profiling technology contributing to a better understanding of disease mechanisms in oncology. OncoSIGNal enables next generation precision medicine by translating molecular data into functional cell behavior.
• Avisi Technologies — Avisi Technologies is developing a nanotechnology-enabled defense against blindness from glaucoma.
• Astrocyte Pharmaceuticals — Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke,TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease.

Portfolio highlights

• Zylö Therapeutics — Patented technology that enables, for topicals, sustained release, increased druggability, a Patchless Patch concept, and enhanced targeting of pores and follicles
• Xeno Biosciences — Xeno Biosciences operates as a biopharmaceutical company pioneering a novel class of therapeutics to address large unmet needs in metabolic diseases. Lead program, XEN-101, is a first-in-class, oral formulation designed to shift the gut microbiome to the weight-loss associated state induced by Roux-en-Y Gastric Bypass (RYGB) surgery.It wasfounded in 2015 and is headquartered in Somerville, Massachusetts.
• Astrocyte Pharmaceuticals — Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke,TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease.

Portfolio highlights

• Hemab — Hemab is pioneering the first preventative treatments and functional cures for patients with rare bleeding and thrombotic disorders.
• ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
• Vicore Pharma — Vicore Pharma is a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders. It develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EUand the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. The company is based in Astra Zeneca’s Bioventurehub in Mölndal.